Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. ADR (NQ: NBTX )

4.930 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. ADR

< Previous 1 2 3 4 5 Next >
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022
From NANOBIOTIX
Via Business Wire
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting
From NANOBIOTIX
Via Business Wire
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3
From NANOBOTIX
Via Business Wire
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results
From NANOBIOTIX
Via Business Wire
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From NANOBIOTIX
Via Business Wire
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer
From Nanobiotix
Via Business Wire
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer
From NANOBIOTIX
Via Business Wire
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022
From Nanobiotix
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference
From Nanobiotix
Via Business Wire
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Provides Third Quarter Operational and Financial Update
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital
From Nanobiotix
Via Business Wire
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May “Reprogram” the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect
From NANOBIOTIX
Via Business Wire
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company’s Share Capital as of August 31, 2021
From Nanobiotix
Via Business Wire
NANOBIOTIX Provides Business Update and Reports Financial Results for the First Half of 2021
From NANOBIOTIX S.A.
Via Business Wire
Nanobiotix to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From NANOBIOTIX
Via Business Wire
Nanobiotix Provides Second Quarter Operational and Financial Update
From NANOBIOTIX
Via Business Wire
NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer
From NANOBIOTIX
Via Business Wire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential First-in-Class Radioenhancer NBTXR3 In Immunotherapy on June 11, 2021
From NANOBIOTIX
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.